ESMO 2022: PRESTO - A Phase 3 Androgen Annihilation in Biochemically Relapsed Prostate Cancer

By The Uromigos - Last Updated: November 11, 2022

Rahul Aggarwal describes the results of the randomized phase 3 PRESTO study that examined the effects of androgen suppressants on biochemically relapsed prostate cancer.

Post Tags:Uromigos-ESMO

Related Podcasts

Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMIBC From SunRISe-1n
Uromigos-Bladder Cancer
Episode 411: Live From EIKCS in Amsterdam - RCC Highlights
Uromigos-Kidney Cancer
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
Uromigos-Bladder Cancer
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in High-Risk NMIBC
Uromigos-Bladder Cancer
Episode 407: Drug Development in China: Part 2 of 2
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |